Scholarlink

Background <p>There is an urgent need for the development of innovative diagnostic and therapeutic strategies in bladder cancer (BlCa) management, due to its significant incidence, mortality, and morbidity. Extracellular vesicles (EVs) constitute promising candidates as biomarkers, as their cargo is highly protected from degradation, and they can be isolated non-invasively from urine. Furthermore, they play a pivotal role in intercellular communication that drives disease progression, making them suitable candidates for tailored therapy approaches.</p> Methods <p>We employed high-throughput mass-spectrometry to perform a comprehensive proteomic analysis of cell lysates and matched EVs. EVs were isolated from six distinct human BlCa cell lines, representatives of the complete disease spectrum, to identify a BlCa-EV associated signature. The translational ability of this signature was analyzed in urinary EV (uEV) samples from BlCa patients and healthy controls.</p> Results <p>This study established a new lysate-to-EV signature that is common to all malignant cell lines. Afterwards, this profile was analyzed in BlCa uEVs, identifying a robust and novel 13-protein BlCa-enriched signature, which includes ITGA2, ITGA6, SCRIB, and TFRC.</p> Conclusion <p>We unveiled a novel, EV-derived protein signature that has potential to be further applied for future functional studies, non-invasive diagnostic assays and targeted therapeutic interventions against BlCa.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From cell lines to the clinic: identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Catarina Lourenço,
  • Vera Constâncio,
  • Nuno Tiago Tavares,
  • Sara Monteiro-Reis,
  • Rui Silva-Santos,
  • João Lobo,
  • Ângela Carvalho,
  • Carmen Jerónimo

摘要

Background

There is an urgent need for the development of innovative diagnostic and therapeutic strategies in bladder cancer (BlCa) management, due to its significant incidence, mortality, and morbidity. Extracellular vesicles (EVs) constitute promising candidates as biomarkers, as their cargo is highly protected from degradation, and they can be isolated non-invasively from urine. Furthermore, they play a pivotal role in intercellular communication that drives disease progression, making them suitable candidates for tailored therapy approaches.

Methods

We employed high-throughput mass-spectrometry to perform a comprehensive proteomic analysis of cell lysates and matched EVs. EVs were isolated from six distinct human BlCa cell lines, representatives of the complete disease spectrum, to identify a BlCa-EV associated signature. The translational ability of this signature was analyzed in urinary EV (uEV) samples from BlCa patients and healthy controls.

Results

This study established a new lysate-to-EV signature that is common to all malignant cell lines. Afterwards, this profile was analyzed in BlCa uEVs, identifying a robust and novel 13-protein BlCa-enriched signature, which includes ITGA2, ITGA6, SCRIB, and TFRC.

Conclusion

We unveiled a novel, EV-derived protein signature that has potential to be further applied for future functional studies, non-invasive diagnostic assays and targeted therapeutic interventions against BlCa.

Graphical Abstract